British American Tobacco - The science behind vapour products: new podcast on ResearchPod published

Quick Navigation

Jump to content

Stories and features

01 August 2023

The science behind vapour products: new podcast on ResearchPod published

Listen to the latest science podcast on ResearchPod. Our scientists share fascinating insights into BAT’s scientific research.

The results from one of the largest ever clinical studies on vaping, which analysed BAT’s flagship vapour brand Vuse, are front and centre in the latest science podcast1 published on ResearchPod  – a platform for science podcasts to connect the global research community.

Nathan Gale, Clinical Studies Manager and Linsey Haswell, Scientist Clinical Research shared fascinating insights into their scientific work at BAT and their latest research, conducting the innovative cross-sectional clinical study of Vuse. The study compared clinical measurements from exclusive Vuse consumers with smokers. The results have been published in the journal of Internal and Emergency Medicine .

Nathan Gale said: “Vaping continues to grow in importance, as adult smokers seek reduced-risk2 alternative nicotine products. It’s been great talking about our research and sharing the latest science behind vapour products in this podcast.”

Linsey Haswell added: “I really enjoyed the conversation and the opportunity to provide some more insight into our daily work in Research and Science . The results of this study are so important for Vuse, BAT and consumers, as they allow us to better understand the positive real-world impact of vaping compared to smoking.”

Vapour products are the most widely studied and accepted alternative tobacco and nicotine products worldwide. BAT’s scientific vapour product data have been published in more than 80 peer-reviewed journals and add to the weight of evidence supporting the category’s role in Tobacco Harm Reduction.

Vuse is the No. 1 global vaping brand by market share and the first global carbon neutral vape brand.   Vuse products are available in 33 markets, with over 10m consumers worldwide.

1 The study focused on self-reported exclusive users of commercially available Vuse ePod or Vuse ePen3. Thus, references to “Vuse” in the context of the study means either Vuse ePod or Vuse ePen3.
Reduced-risk product statements are based on the weight of evidence and assuming a complete switch from cigarette smoking.  These products are not risk-free and are addictive. Our products as sold in the U.S., including Vuse, Velo, Grizzly, Kodiak, and Camel Snus, are subject to Food and Drug Administration (FDA) regulation and no reduced-risk claims will be made as to these products without FDA clearance.
This podcast is not intended as a piece of promotional material for any products. This update relates to new scientific data and is not aimed at a specific market. It is intended to provide further scientific evidence to underpin our products.
Less toxicants statements are based on a comparison of smoke from a scientific standard reference cigarette (approximately 9 mg tar) and emissions from Vuse in terms of the average of the 9 harmful components the World Health Organisation recommends to reduce in cigarette smoke. For Velo, the comparison is based on the components released during use of a Velo pouch.
2 Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk-free and are addictive.